{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:54:20Z","timestamp":1777312460632,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH) is a rare, progressive phosphate-wasting disorder that leads to significant skeletal morbidity and pain. The current study used real-world administrative claims data to assess the demographic and clinical characteristics of patients with XLH related to claims for prescription pain medication (PPM) during the 12 mo before starting burosumab treatment (baseline) and explores changes in PPM claims after starting burosumab treatment. Claims for XLH-related musculoskeletal and deformity-related conditions, obesity, and osteoarthritis were common among the adult cohort (n\u00a0=\u2009387). Claims for PPM (vs no claims) during baseline were significantly (p\u00a0&amp;lt;\u2009.05) associated with: age\u2009\u2265\u200950\u00a0yr (odds ratio [OR] 2.54), Medicaid coverage (2.25), myalgia (2.54), scoliosis (3.19), obesity (2.07), dental complications (2.53), and physical therapy (2.94). Approximately half of the adult cohort (54%) made PPM claims during baseline, and 38% for opioids, with little change after starting burosumab. Claims for arthralgia, hip\/leg deformities and rickets were common in pediatric patients (n\u00a0=\u2009524). Claims for PPM were significantly associated with race (OR 0.13), chronic pulmonary disease (4.34), renal disease (4.88), arthralgia (2.20), cholecalciferol claims (1.93), and physical therapy (3.48). About one-fifth of pediatric patients (25%) had claims for PPM prescriptions during baseline, with little change after 12 mo, but showed a modest decrease during the second year of follow-up; 12%-17% of pediatric patients had claims for opioids during baseline and follow-up. The number of days covered by opioid prescriptions was lower in pediatric patients than in adults. Multiple factors are associated with PPM use in patients with XLH. Understanding these factors may inform patient-centered pain management strategies. A longer study is needed to determine how burosumab treatment affects pain and the use of PPM in patients with XLH.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag047","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:19:15Z","timestamp":1774268355000},"source":"Crossref","is-referenced-by-count":0,"title":["Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1760-9678","authenticated-orcid":false,"given":"Carolyn M","family":"Macica","sequence":"first","affiliation":[{"name":"University of Connecticut School of Medicine and Connecticut Children\u2019s Research Institute , Department of Research Operations and Development, Hartford, CT 06106 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0779-9720","authenticated-orcid":false,"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , HEOR, Princeton, NJ 08540 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International , HEOR, Marlow SL7 1HZ ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Noman","sequence":"additional","affiliation":[{"name":"Komodo Health Inc. , New York , NY 10010,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Park","sequence":"additional","affiliation":[{"name":"Komodo Health Inc. , New York , NY 10010,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina N","family":"Woods","sequence":"additional","affiliation":[{"name":"UC San Diego Health , School of Medicine, CA 92093\u20130602 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026042713192266200_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221117471","article-title":"Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description","volume":"13","author":"Brandi","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2026042713192266200_ref2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2026042713192266200_ref3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/sca.21141","article-title":"X-linked hypophosphatemic rickets: enamel abnormalities and oral clinical findings","volume":"36","author":"Cremonesi","year":"2014","journal-title":"Scanning."},{"issue":"7","key":"2026042713192266200_ref4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00198-022-06318-w","article-title":"Physical function and physical activity in adults with X-linked hypophosphatemia","volume":"33","author":"Orlando","year":"2022","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026042713192266200_ref5","doi-asserted-by":"crossref","DOI":"10.3390\/genes13122415","article-title":"Impact of X-linked hypophosphatemia on muscle symptoms","volume":"13","author":"Romagnoli","year":"2022","journal-title":"Genes (Basel)"},{"issue":"7","key":"2026042713192266200_ref6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"issue":"Suppl 2","key":"2026042713192266200_ref7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s13023-023-02883-3","article-title":"XLH matters 2022: insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)","volume":"18","author":"Seefried","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026042713192266200_ref8","doi-asserted-by":"crossref","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"issue":"1","key":"2026042713192266200_ref9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00223-025-01374-w","article-title":"The diagnosis and therapy of XLH","volume":"116","author":"Bockmann","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2026042713192266200_ref10","doi-asserted-by":"crossref","first-page":"bvab070.","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course","volume":"5","author":"Cheung","year":"2021","journal-title":"J Endocr Soc."},{"issue":"1","key":"2026042713192266200_ref11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11657-025-01544-1","article-title":"Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab","volume":"20","author":"Dahir","year":"2025","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2026042713192266200_ref12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026042713192266200_ref13","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf104","article-title":"Pain, quality of life and mental health in adults with X-linked hypophosphatemia: a cross-sectional study","volume":"110","author":"Diaz-delCastillo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042713192266200_ref14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026042713192266200_ref15","doi-asserted-by":"crossref","first-page":"ziae102","DOI":"10.1093\/jbmrpl\/ziae102","article-title":"Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring program","volume":"8","author":"Khan","year":"2024","journal-title":"JBMR Plus"},{"issue":"4","key":"2026042713192266200_ref16","doi-asserted-by":"crossref","first-page":"ziaf012","DOI":"10.1093\/jbmrpl\/ziaf012","article-title":"Qualitative analysis of pain impact in adult patients with X-linked hypophosphatemia","volume":"9","author":"Nishime","year":"2025","journal-title":"JBMR Plus."},{"key":"2026042713192266200_ref17","volume-title":"Crysvita Prescribing Information","author":"FDA","year":"2018"},{"issue":"4","key":"2026042713192266200_ref18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","article-title":"Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study","volume":"111","author":"Brandi","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2026042713192266200_ref19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"10189","key":"2026042713192266200_ref20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"issue":"8","key":"2026042713192266200_ref21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026042713192266200_ref22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026042713192266200_ref23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002676","article-title":"Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenicky","year":"2023","journal-title":"RMD Open"},{"issue":"3","key":"2026042713192266200_ref24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042713192266200_ref25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042713192266200_ref26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2026042713192266200_ref27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"2026042713192266200_ref28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2026042713192266200_ref29","doi-asserted-by":"crossref","first-page":"e1798","DOI":"10.1210\/clinem\/dgaa064","article-title":"Osteoarthritis, osteophytes, and enthesophytes affect biomechanical function in adults with X-linked hypophosphatemia","volume":"105","author":"Steele","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026042713192266200_ref30","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.1210\/clinem\/dgab282","article-title":"Incidence of complications in 25 adult patients with X-linked hypophosphatemia","volume":"106","author":"Kato","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026042713192266200_ref31","doi-asserted-by":"crossref","first-page":"ziaf113","DOI":"10.1093\/jbmrpl\/ziaf113","article-title":"Prevalence of enthesopathies in X-linked hypophosphatemia: an explorative ultrasound study","volume":"9","author":"Bachfischer","year":"2025","journal-title":"JBMR Plus."},{"key":"2026042713192266200_ref32","doi-asserted-by":"crossref","first-page":"1211426.","DOI":"10.3389\/fendo.2023.1211426","article-title":"Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives","volume":"14","author":"Seefried","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026042713192266200_ref33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ejendo\/lvae089","article-title":"Metabolically healthy obesity in adults with X-linked hypophosphatemia","volume":"191","author":"Lecoq","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026042713192266200_ref34","first-page":"e28416","article-title":"Chronic pain-induced depression: a review of prevalence and management","volume":"14","author":"Meda","year":"2022","journal-title":"Cureus."},{"issue":"2","key":"2026042713192266200_ref35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.sjpain.2011.01.005","article-title":"Understanding the link between depression and pain","volume":"2","author":"Linton","year":"2011","journal-title":"Scand J Pain"},{"issue":"8","key":"2026042713192266200_ref36","doi-asserted-by":"crossref","first-page":"bvac094","DOI":"10.1210\/jendso\/bvac094","article-title":"An evidence-based physical therapy prescription for adults with X-linked hypophosphatemia","volume":"6","author":"Kanamalla","year":"2022","journal-title":"J Endocr Soc."},{"key":"2026042713192266200_ref37","volume-title":"FastStats: Obesity and Overweight","author":"National Center for Health Statistics","year":"2025"},{"key":"2026042713192266200_ref38","article-title":"Centers for Disease Control. National Diabetes Statistics","year":"2024","journal-title":"Report."},{"issue":"5","key":"2026042713192266200_ref39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amepre.2022.05.014","article-title":"Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap","volume":"63","author":"Goodwin","year":"2022","journal-title":"Am J Prev Med"},{"issue":"6","key":"2026042713192266200_ref40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/cge.13440","article-title":"A multicenter study to evaluate pulmonary function in osteogenesis imperfecta","volume":"94","author":"Tam","year":"2018","journal-title":"Clin Genet"},{"issue":"12","key":"2026042713192266200_ref41","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"21","key":"2026042713192266200_ref42","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with x-linked hypophosphatemia","volume":"378","author":"Carpenter TO","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2026042713192266200_ref43","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/clinem\/dgae398","article-title":"Improved oral health in adults with X-linked hypophosphatemia treated with burosumab","volume":"110","author":"Herve","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026042713192266200_ref44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","article-title":"Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia","volume":"40","author":"Florenzano","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026042713192266200_ref45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.berh.2013.09.011","article-title":"Long-term use of opioids for complex chronic pain","volume":"27","author":"Von Korff","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"2026042713192266200_ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag047\/67499516\/ziag047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/5\/ziag047\/67499516\/ziag047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/5\/ziag047\/67499516\/ziag047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:19:32Z","timestamp":1777310372000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag047\/8539703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag047","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,24]]},"article-number":"ziag047"}}